公开(公告)号：EP1383539B1

公开(公告)日：2006-07-26

申请号：EP02758920.9

申请日：2002-08-14

Applicant: Korea Institute of Science and Technology ,  Jakwang Co., Ltd.

Inventor： KWON, Ick Chan ,  KIM, In-San ,  JEONG, Seo Young ,  CHUNG, Hesson ,  CHO, Yong Woo ,  SON, Yoen Ju, 106-1404 Sinkongduk samsung Apt. ,  PARK, Chong Rae, Ga-102 Seoul Univ. kyosu Apt. ,  SEO, Sang, Bong

IPC: A61P35/00

CPC classification number: A61K31/704 ,  A61K47/61 ,  A61K47/6907

Abstract: The present invention relates to an anticancer drug-chitosan complex forming self-aggregates and the preparation method thereof. More precisely, the present invention relates to the anticancer drug-chitosan complex forming self-aggregates in aqueous media composed of a hydrophobic anticancer agent and a hydrophilic chitosan, and the preparation method thereof. The anticancer drug-chitosan complex of the present invention not only works selectively against target tumor tissue but also continues to release the medicine over a long period of time. Besides, the anticancer drug-chitosan complex could have greater amount of drug by adding the anticancer drug into self-aggregates, which is generally limited by chemical bond. Therefore, the anticancer drug-chitosan complex of the present invention can be effectively used for the cancer chemotherapy.

公开(公告)号：EP1545499A1

公开(公告)日：2005-06-29

申请号：EP03741592.4

申请日：2003-07-18

Applicant: Korea Institute of Science and Technology

Inventor： CHUNG, Hesson ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  PARK, Yeong-Taek ,  LEE, In-Hyun ,  YUK, Soon-Hong ,  CHOI, Young-Wook ,  PARK, Jae-Hyung ,  CHUNG, Jin-Wook

IPC: A61K31/337

CPC classification number: A61K31/337 ,  A61K9/0019 ,  A61K9/0095 ,  A61K9/107 ,  A61K45/06 ,  A61K47/10 ,  A61K47/14 ,  A61K47/44 ,  A61K2300/00

Abstract: The present invention relates to a paclitaxel composition and the preparation methods thereof to solubilize paclitaxel wherein said composition comprises 4~90% by weight of at least one selected from the monoglycerides, 0.01~90% by weight of at least one oil and 0.01~20% by weight of paclitaxel. Also the present invention relates to a paclitaxel composition including emulsifiers and the preparation methods thereof to solubilize paclitaxel wherein said composition comprises 4~90% by weight of at least one selected from the monoglycerides, 0.01~90% by weight of at least one oil, 0.01~90% by weight of at least one emulsifier and 0.01~20% by weight of paclitaxel. The composition of the present invention is an effective paclitaxel delivery system since the composition solubilizes paclitaxel, does not form aggregates after being dispersed in water, adsorbs well on the intestinal wall, and therefore has high bioavailability.

公开(公告)号：EP1263468A1

公开(公告)日：2002-12-11

申请号：EP01912555.8

申请日：2001-03-13

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： JEONG, Seo Young ,  KWON, Ick Chan ,  CHUNG, Hesson

IPC: A61K47/06

CPC classification number: A61K9/1075 ,  A61K9/19

Abstract: The present invention relates to an anhydrous liquid composition wherein monoglyceride is mixed with an emulsifier and a solvent, and the manufacturing method thereof, and more specifically, to an anhydrous liquid composition wherein monoglyceride is mixed with a water-insoluble material, an emulsifier and a solvent, and the manufacturing method thereof. Further, the present invention relates to a lyophilized powder and the manufacturing method thereof, wherein the lyophilized powder is prepared by dissolving the mixed liquid composition in water, adding with a cryoprotectant followed by the lyophilization. In the process of dispersion, the lyophilized liquid composition and the powder of the present invention can spontaneously generate particles of 200-500 nm by gently shaking with hands without a powerful mechanical force. Also the lyophilized liquid composition and the powder of the present invention are physicochemically stable since they neither contain water that causes oxidation or hydrolysis upon storage nor undergo phase separation. Considering all the raw materials of the present invention are biocompatible, the present invention will be useful in medical and pharmaceutical fields such as drug delivery.